Indivior's opioid addiction sprat approved by FDA
Indivior
782.00p
15:44 15/11/24
-1.01%
-8.00p
US health regulators have approved Indivior’s Opvee nasal spray treatment for opiod addiction, the company said on Tuesday.
FTSE 250
20,508.75
15:45 15/11/24
n/a
n/a
FTSE 350
4,453.56
15:45 15/11/24
n/a
n/a
FTSE All-Share
4,411.85
15:45 15/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
-2.70%
-535.19
The drug will help combat overdoses caused by fentanyl and other opioids dtiving America’s drug crisis. Opvee works by blocking the effects of opioids in the brain, which can restore breathing and blood pressure in people who have recently overdosed.
“Opvee’s Food and Drug Administration's approval represents a significant achievement in the development of new treatment options to address today's era of opioid overdoses that are driven by powerful synthetic opioids, such as fentanyl," said chief executive Mark Crossley.
Reporting by Frank Prenesti for Sharecast.com